Workshop: AML mutation detection using error-corrected sequencing
Acute myeloid leukemia (AML) is a clonally heterogeneous cancer where the landscape of mutations is highly variable between children and adults, involving complex chromosomal translocations, indels and single nucleotide variants (SNVs). Traditional molecular assays rely upon multiple platforms to identify mutations but generally lack quantitation of rare clones. Advances in sequencing-based methods enable comprehensive detection of gene fusions, SNVs, gene expression and internal tandem duplications. From Washington University, now ArcherDX CMO, Dr. Todd Druley describes his use of error-corrected sequencing coupled with powerful bioinformatics to detect rare clonal variants in adult and pediatric AML.
Webinar: Validation of Error-Corrected Sequencing for Hematological Malignancies
In this webinar, Drs. Catherine Rehder and Sarah Rapisardo, at Duke University, describes their efforts to validate the VariantPlex® Myeloid assay. They also discuss their work to expand testing with a custom FusionPlex® assay to detect known and novel fusions, with a focus on Ph-like acute lymphoblastic leukemia (ALL) fusions.
UTILITY OF ANCHORED MULTIPLEX PCR FOR GENE FUSION DETECTION
Cecilia Yeung, MD., from Fred Hutchinson Cancer Research Center, discusses how she is using Anchored Multiplex PCR (AMP™) technology for rapid identification of fusions in leukemias with Oxford Nanopore™ real-time sequencing. This webinar was recorded on August 7, 2018.
Plasma Mutation Panel
In this AMP 2017 workshop, Dr. Margaret L. Gulley, from UNC School of Medicine, describes her ability to confidently detect variants and viral markers in plasma DNA using targeted NGS coupled with powerful bioinformatics.
FLT3-ITD Detection With Blood Cancer Assays
The molecular landscape of leukemia and lymphoma has expanded exponentially in the last two decades, and the complexity and scope of biomarkers makes molecular analysis difficult for any single approach. FusionPlex® and VariantPlex® assays are powered by Anchored Multiplex PCR (AMP™) target enrichment chemistry to detect multiple mutation types and gene expression profiling in a single sample.
Why RNA is Better for Fusion Detection
Why do FusionPlex® assays use RNA instead of DNA for input material? It all comes down to biological relevance, cost, and turn-around time. See why RNA is better for fusion detection than DNA-based hybrid capture techniques.
AMP™ is Better: Strand Specificity
See how Anchored Multiplex PCR (AMP™) chemistry is better than traditional opposing primer-based enrichment, because strand-specific priming allows you to identify and correct for deamination events that would otherwise lease to false-positive results.
FusionPlex® Anchored Multiplex PCR (AMP™) Chemistry
Learn how the FusionPlex® System utilizes Anchored Multiplex PCR (AMP™) chemistry to create target enriched RNA libraries for next-generation sequencing (NGS).
AMP™ is Better for Novel Gene Fusion Detection
Anchored Multiplex PCR (AMP™) enables the detection of targets of interest, including any known or novel fusion partners by using target-specific primers uni-directional primers, along with reverse primers, that hybridize to the sequencing adapter that is ligated to each fragment prior to amplification.
Molecular Barcode Adapters
Anchored Multiplex PCR (AMP™) technology utilizes Molecular Barcode (MBC) Adapters for error correction, sample identification, de duplication, and advanced analysis in targeted sequencing NGS applications.